Skip to main content

Table 1 Baseline characteristics of African American and Caucasian research participants

From: Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers

 

Overall

Normal cognition

MCI

AD

African American (n = 65)

Caucasian (n = 70)

African American (n = 27)

Caucasian (n = 29)

African American (n = 27)

Caucasian (n = 25)

African American (n = 11)

Caucasian (n = 16)

Age, years (SD)

69.1 (7.4)

70.8 (7.7)

67.5 (6.2)

71.4 (8.1)

67.7 (7.6)

71.5 (5.8)

71.4 (9.1)

68.5 (9.4)

Male sex, n (%)

29 (45%)

29 (41%)

10 (37%)

12 (41%)

15 (56%)

10 (40%)

4 (36%)

7 (44%)

Education, years (SD)

16.1 (2.8)

16.4 (2.7)

15.8 (2.7)

17.0 (2.6)

16.3 (2.9)

17.1 (2.6)

16.7 (3.4)

14.2 (1.9)

MMSE (SD)

26.1 (4.0)

26.7 (3.6)

28.0 (1.8)

28.9 (0.8)

26.6 (2.4)

27.6 (1.7)

20.5 (5.9)

21.4 (3.4)

Hypertension

47 (72%)a

32 (46%)

17 (63%)

13 (45%)

21 (78%)

14 (56%)

9 (82%)

5 (31%)

Diabetes

22 (34%)a

4 (6%)

9 (33%)

2 (7%)

8 (30%)

0

5 (45%)

2 (12%)

Average number of vascular risk factors (SD)

1.9 (1.2)a

1.3 (1.1)

1.5 (1.1)

1.3 (1.3)

2.2 (1.3)

1.4 (0.9)

2.2 (1.2)

1.0 (1.0)

Having at least one APOE ε4 allele, n (%)

31/60 (52%)

35/70 (50%)

7/25 (29%)

11 (38%)

15/26 (58%)

13 (52%)

9/10 (90%)

11 (69%)

Having ABCA7 risk allele, n (%)

28/60 (47%)a

16/70 (23%)

12/25 (48%)

8 (27%)

13/25 (52%)

6 (24%)

3/10 (30%)

2 (12%)

Completed LP, n (%)

58 (89%)

68 (97%)

23 (85%)

28 (97%)

25 (93%)

25 (100%)

10 (91%)

15 (94%)

CSF

 Aβ42, pg/ml (SD)

212.3 (118)

207.2 (148)

273 (110)

250 (131)

178 (110)

226 (172)

158 (105)

96 (61)

 Aβ40, ng/ml (SD)

7.89 (2.92)

9.29 (3.32)

7.21 (1.96)a

10.03 (3.65)

7.83 (3.21)

9.38 (3.18)

9.49 (3.61)

7.91 (2.54)

 t-Tau, pg/ml (SD)

47.0 (31.1)a

71.5 (47.8)

36.3 (12.0)a

58.6 (29.0)

46.4 (38.6)

66.6 (38.4)

72.8 (27.5)

103.8 (72.9)

 p-Tau181, pg/ml (SD)

17.9 (9.3)a

25.6 (12.6)

13.8 (5.1)a

22.5 (9.8)

18.8 (10.2)

24.0 (12.0)

25.3 (10.3)

34.2 (14.9)

CSF t-Tau/Aβ42 > 0.39

17/58 (29%)

31/68 (46%)

2/23 (9%)

7/28 (25%)

9/25 (36%)

13/25 (52%)

6/10 (60%)

11/15 (73%)

Log10(NfL), ng/ml (SD)

2.87 (0.27)

2.97 (0.19)

2.76 (0.23)

2.96 (0.22)

2.87 (0.26)

2.96 (0.15)

3.14 (0.23)

3.02 (0.22)

Log10(WMH), cm3 (SD)

0.367 (0.453)

0.437 (0.364)

0.238 (0.337)

0.355 (0.365)

0.401 (0.515)

0.483 (0.308)

0.607 (0.466)

0.514 (0.431)

  1. Abbreviations: Aβ40 β-Amyloid 1–40, Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, APOE Apolipoprotein E, CSF Cerebrospinal fluid, MCI Mild cognitive impairment, MMSE Mini Mental State Examination, NfL Neurofilament light chain, p-Tau 181 Tau phosphorylated at threonine 181, t-Tau Total tau, WMH White matter hyperintensity
  2. Values shown are unadjusted
  3. aValues or proportions differed between the two races (p < 0.005)
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193